BlackRock Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

BlackRock Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.85M	Buy	85,043 +12,417	+17%	+$356K	﹤0.01%	1974
2016 Q3	$1.93M	Buy	72,626 +96	+0.1%	+$2.23K	﹤0.01%	2185
2016 Q2	$1.6M	Buy	72,530 +8,836	+14%	+$231K	﹤0.01%	2291
2016 Q1	$1.87M	Buy	63,694 +1,209	+2%	+$33.7K	﹤0.01%	2051
2015 Q4	$2.06M	Buy	62,485 +171	+0.3%	+$5.57K	﹤0.01%	2066
2015 Q3	$2.25M	Buy	62,314 +5,505	+10%	+$236K	﹤0.01%	1992
2015 Q2	$2.56M	Buy	56,809 +26,467	+87%	+$1.03M	﹤0.01%	2030
2015 Q1	$929K	Buy	30,342 +363	+1%	+$14.1K	﹤0.01%	2569
2014 Q4	$1.52M	Sell	29,979 -78	-0.3%	-$3.49K	﹤0.01%	2244
2014 Q3	$1.19M	Buy	30,057 +143	+0.5%	+$5.7K	﹤0.01%	2401
2014 Q2	$1.29M	Buy	29,914 +19,588	+190%	+$747K	﹤0.01%	2418
2014 Q1	$413K	Buy	10,326 +208	+2%	+$7.55K	﹤0.01%	3049
2013 Q4	$276K	Sell	10,118 -5	-0%	-$121	﹤0.01%	3164
2013 Q3	$232K	Buy	10,123 +1,035	+11%	+$19.8K	﹤0.01%	3160
2013 Q2	$161K	Buy	+9,088	New	+$177K	﹤0.01%	3190

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's ENTA Position: Q4 2016 in Review

BlackRock Investment Management increased its Enanta Pharmaceuticals (ENTA) stake by 17% in Q4 2016, buying an estimated $356K and bringing the position to 85,043 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1974.

BlackRock Investment Management first reported a position in ENTA in Q2 2013 and has held it in 15 quarters since. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

BlackRock Investment Management held 85,043 shares of Enanta Pharmaceuticals worth $2.85M as of Q4 2016.
BlackRock Investment Management bought 12,417 Enanta Pharmaceuticals shares in Q4 2016, an estimated $356K.
Enanta Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1974 holding.
BlackRock Investment Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.